Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6186334 | 0.91 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1KDM4ETDP1MAPT | |
| SCHEMBL24838807 | 0.89 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL13400097 | 0.87 | HDAC1 (0.50) | ALDH1A1MAPTHDAC1HDAC6SMN1; SMN2 | |
| SCHEMBL19553511 | 0.87 | NAMPT (0.44) | ALDH1A1L3MBTL1HDAC1 | |
| SCHEMBL2037435 | 0.86 | CYP1A2 (0.43) | ALDH1A1L3MBTL1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL7370094 | 0.85 | TRPV1 (0.61) | ALDH1A1KDM4EHDAC1 | |
| SCHEMBL6681923 | 0.85 | ALDH1A1 (0.52) | ALDH1A1L3MBTL1HDAC1KMT2AMEN1 | |
| SCHEMBL31142951 | 0.85 | ALDH1A1 (0.48) | ALDH1A1L3MBTL1HDAC1HDAC6SMN1; SMN2 | |
| SCHEMBL2043513 | 0.84 | CYP2D6 (0.43) | ALDH1A1L3MBTL1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL1985433 | 0.83 | HDAC1 (0.51) | L3MBTL1HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327354-A1 | GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS | INSTITUT PASTEUR DE LILLE (FR) | 2024-10-03 | — | — | US | disclosed |
| WO-2023002011-A1 | GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-01-26 | — | — | WO | disclosed |
| EP-0979227-B1 | 4,1-BENZOXAZEPINES, THEIR ANALOGUES, AND THEIR USE AS SOMATOSTATIN AGONISTS | TAKEDA PHARMACEUTICAL (JP) | 2005-11-16 | — | — | EP | disclosed |
| US-6352982-B1 | TREATING DIABETES, OBESITY, OR INVETERATE DIARRHEA IN A MAMMAL WHICH COMPRISES ADMINISTERING AN EFFECTIVE AMOUNT OF A COMPOUND OF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-03-05 | — | — | US | disclosed |
| EP-0979227-A1 | 4,1-BENZOXAZEPINES, THEIR ANALOGUES, AND THEIR USE AS SOMATOSTATIN AGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2000-02-16 | — | — | EP | disclosed |
| WO-1998047882-A1 | 4,1-BENZOXAZEPINES, THEIR ANALOGUES, AND THEIR USE AS SOMATOSTATIN AGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327354-A1 | GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, ATP4B | ALDH1A1 4679/4885L3MBTL1 3065/4885KDM4E 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.